复方苦参注射液联合培美曲塞二线治疗晚期非小细胞肺癌112例临床观察

Efficacy and Safety of Compound Kushen Injection Combined with Pemetrexed as Second-line Therapy for Advanced Non-small Cell Lung Cancer: Clinical Observation on 112 Cases

目的:观察复方苦参注射液联合培美曲塞二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法:112例晚期NSCLC一线化疗失败患者分为对照组56例和治疗组56例,均采用培美曲塞方案化疗,治疗组加用复方苦参注射液,完成2～4个周期后进行疗效评价。结果:2组近期疗效、中位疾病无进展时间无显著差异,生活质量的改善及体重增加方面治疗组优于对照组,不良反应方面治疗组轻于对照组。结论:复方苦参注射液联合培美曲塞二线治疗晚期非小细胞肺癌患者,疗效尚可,具有改善患者的生活质量及减轻化疗不良反应的作用。

OBJECTIVE：To evaluate the clinical efficacy and toxicity of compound Kushen injection combined with pemetrexed as the second-line therapy for advanced non-small cell lung cancer（NSCLC）.METHODS： A total of 112 patients with advanced NSCLC which hadn＇t resolved with first-line chemotherapy were divided into two groups,of 56 each.The treatment group received Pemetrexed plus compound Kushen injection while the control group received pemetrexed alone.The efficacy was compared between the two groups after treatment of 2-4 cycles.RESULTS： There were no significant differences in short-term efficacy and median progression-free time between two groups;however,the treatment group showed better improvement in the quality of life and weight gain bit milder adverse reactions than in the control group.CONCLUSION： The regimen of compound Kushen injection combined with pemetrexed as a second-line therapy for advanced NSCLC patients was effective in that it improved patients＇ quality of life meanwhile attenuating the toxicity of the chemotherapy.